Recombinant Vaccine Technologies: From Experimental Levels to Commercial Products
Submission Deadline: Sep. 30, 2015
Lead Guest Editor
Genomics Lab, Biotechnology Department, Razi Vaccine and Serum Research Institute,
Karaj, Alborz, Iran
Biotechnology Department, Razi Vaccine & Serum Research Institute,
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=216). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Development of vaccination as a tool in fighting disease has resulted in the potential to combat almost all infec¬tious agents affecting people and ani¬mals. Vaccination usually is accom¬plished with either weakened or attenu¬ated live agents; with inactivated agents that no longer can cause disease; or with selected, immunogenic parts of the disease agent called subunit vaccines. Traditional methods of creating vac¬cines include using a similar agent that does not cause disease, or passing a pathogenic disease agent through a laboratory host system to weaken or attenuate the agent. Inactivating the disease agent with one or more chemicals also can be used to create vaccines. In addition, extracting, purifying, and using one or more parts of the disease agent can be used to in¬duce a protective immune response. Although vaccination has saved countless lives, it can have both favor¬able and unfavorable consequences. Some traditional vaccines, specifically live vac¬cines, can revert back to pathogenic or¬ganisms and produce disease or, in some instances, even death. The development biotechnology, specifically recombinant DNA (rDNA) technologies, has provided new ways of attenuating disease agents by manipulating their genetic makeup, genes, or ge¬nomes, to create safer, more efficacious vaccines. Using rDNA technologies, scientists have been able to develop several types of recombinant vaccines: (1) live geneti¬cally modified organisms, (2) recombi¬nant inactivated (“killed”) vaccines, and (3) genetic vaccines. These vaccines no longer cause disease, but still induce a strong immune response. Paralleling the development of new, more efficacious, stable, and safe recombinant vaccines has been the study of immunostimulating adju¬vant compounds that enhance the im¬mune response. New efforts need to target the development of vaccines for diseases for which poorly effective vac¬cines are currently in use and also economi¬cally important diseases for which no currently available vaccines exist advances in recombinant DNA technology, in knowledge of the host immune re¬sponse, and in the genetic makeup of disease agents will lead to new vac¬cines against diseases that currently have few or no control measures. Original research papers are solicited in any aspect of recombinant vaccine technology.
Aims and Scope: Recombinant Human Vaccines - infectious diseases Recombinant Human Vaccines - non-infectious diseases Recombinant Veterinary Vaccines Recombinant Vectors and Adjuvants Production, manufacturing Recombinant Vaccine Safety